Jiangsu Nhwa Pharmaceutical Co Ltd (002262) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jiangsu Nhwa Pharmaceutical Co Ltd (002262) has a cash flow conversion efficiency ratio of 0.053x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥425.83 Million ≈ $62.31 Million USD) by net assets (CN¥8.08 Billion ≈ $1.18 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 002262 market cap overview for the company's overall valuation and market capitalisation.
Jiangsu Nhwa Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Jiangsu Nhwa Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Jiangsu Nhwa Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jiangsu Nhwa Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Explore 002262 cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tofas Turk Otomobil Fabrikasi AS
IS:TOASO
|
-0.093x |
|
BBB Foods Inc.
NYSE:TBBB
|
0.266x |
|
Sichuan Chemical Co Ltd
SHE:000155
|
0.057x |
|
BankUnited Inc
NYSE:BKU
|
0.043x |
|
Almonty Industries Inc
TO:AII
|
0.026x |
|
EQB Inc.
TO:EQB
|
-0.163x |
|
Salzgitter AG
XETRA:SZG
|
0.015x |
|
Epoxy Base Electronic Material Corp Ltd
SHG:603002
|
0.002x |
Annual Cash Flow Conversion Efficiency for Jiangsu Nhwa Pharmaceutical Co Ltd (2005–2025)
The table below shows the annual cash flow conversion efficiency of Jiangsu Nhwa Pharmaceutical Co Ltd from 2005 to 2025. View 002262 share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥8.03 Billion ≈ $1.17 Billion |
CN¥1.08 Billion ≈ $157.80 Million |
0.134x | +6.65% |
| 2024-12-31 | CN¥7.27 Billion ≈ $1.06 Billion |
CN¥916.13 Million ≈ $134.06 Million |
0.126x | -19.93% |
| 2023-12-31 | CN¥6.41 Billion ≈ $938.00 Million |
CN¥1.01 Billion ≈ $147.55 Million |
0.157x | +2.01% |
| 2022-12-31 | CN¥5.58 Billion ≈ $817.07 Million |
CN¥861.02 Million ≈ $125.99 Million |
0.154x | +7.85% |
| 2021-12-31 | CN¥4.90 Billion ≈ $717.57 Million |
CN¥701.12 Million ≈ $102.60 Million |
0.143x | -52.98% |
| 2020-12-31 | CN¥4.11 Billion ≈ $600.76 Million |
CN¥1.25 Billion ≈ $182.67 Million |
0.304x | +258.24% |
| 2019-12-31 | CN¥3.60 Billion ≈ $527.50 Million |
CN¥305.97 Million ≈ $44.77 Million |
0.085x | -37.93% |
| 2018-12-31 | CN¥2.96 Billion ≈ $432.87 Million |
CN¥404.52 Million ≈ $59.19 Million |
0.137x | -25.59% |
| 2017-12-31 | CN¥2.46 Billion ≈ $360.17 Million |
CN¥452.35 Million ≈ $66.19 Million |
0.184x | +40.84% |
| 2016-12-31 | CN¥2.12 Billion ≈ $310.80 Million |
CN¥277.14 Million ≈ $40.55 Million |
0.130x | +16.75% |
| 2015-12-31 | CN¥1.83 Billion ≈ $267.39 Million |
CN¥204.24 Million ≈ $29.89 Million |
0.112x | -26.13% |
| 2014-12-31 | CN¥1.06 Billion ≈ $154.97 Million |
CN¥160.24 Million ≈ $23.45 Million |
0.151x | -34.89% |
| 2013-12-31 | CN¥836.21 Million ≈ $122.36 Million |
CN¥194.33 Million ≈ $28.44 Million |
0.232x | +2.88% |
| 2012-12-31 | CN¥682.44 Million ≈ $99.86 Million |
CN¥154.16 Million ≈ $22.56 Million |
0.226x | +54.92% |
| 2011-12-31 | CN¥556.01 Million ≈ $81.36 Million |
CN¥81.08 Million ≈ $11.86 Million |
0.146x | +9.15% |
| 2010-12-31 | CN¥462.56 Million ≈ $67.69 Million |
CN¥61.79 Million ≈ $9.04 Million |
0.134x | -13.66% |
| 2009-12-31 | CN¥396.00 Million ≈ $57.95 Million |
CN¥61.27 Million ≈ $8.97 Million |
0.155x | +14.38% |
| 2008-12-31 | CN¥343.75 Million ≈ $50.30 Million |
CN¥46.50 Million ≈ $6.80 Million |
0.135x | -57.54% |
| 2007-12-31 | CN¥152.39 Million ≈ $22.30 Million |
CN¥48.55 Million ≈ $7.10 Million |
0.319x | +26.12% |
| 2006-12-31 | CN¥122.67 Million ≈ $17.95 Million |
CN¥30.99 Million ≈ $4.53 Million |
0.253x | +259.29% |
| 2005-12-31 | CN¥125.74 Million ≈ $18.40 Million |
CN¥8.84 Million ≈ $1.29 Million |
0.070x | -- |
About Jiangsu Nhwa Pharmaceutical Co Ltd
Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin… Read more